BEIJING, April 25, 2025 /PRNewswire/ -- Baijiayun Group Ltd ("Baijiayun" or the "Company") (NASDAQ: RTC), a one-stop AI video solution provider, announced a Letter to Investors, in which Baijiayun CEO Mr. Yi Ma stated that following its partnership with Xinlantian, the company plans to invest tens of millions of dollars over the next five years to establish new ecosystem for autism rehabilitation.

SHELTON, Conn., April 25, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the pricing of its "reasonable best efforts" public offering with participation from certain new and existing institutional and accredited investors for the purchase and sale of 3,133,333 shares of its common stock (or common stock equivalents in lieu thereof) and accompanying Series B-1 common warrants to purchase up to 3,133,333 shares of common stock ...

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression. HARMONi-2 is a single region, multi-center, Phase III study conducted in China sponsored by Akeso with all relevant data exclusively generated, managed, and ...

VANCOUVER, B.C., April 25, 2025 /PRNewswire/ -- Equity Insider News Commentary – The way people consume beverages is changing, both in terms of what they're drinking and how they're buying it. Functional and fortified drinks are gaining ground, with analysts at Insight Ace Analytic forecasting the category to grow at a 7.9% annual rate through 2035. Industry watchers now consider functional beverages one of the fastest-expanding segments within the broader wellness market. This shift hasn't gone unnoticed by investors, especially as companies across the sector continue to roll out new products and strategies to capture demand,  including Safety Shot, Inc. ...